Endocrine oncology (Bristol, England) · 2026
CHEK2 germline gene variant in a patient with a somatotrophinoma and primary hyperparathyroidism: a novel MEN1-like syndrome?
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arjunan Durairaj, Bhat Mohammad Hayat, Rai Ashutosh, Kaur Vaishali, Barry Sayka, Alam Md Ejaz, Baba Mohammad Salem, Gulati Ajay, Chatterjee Debajyoti, Latoo Manzoor Ahmad, Korbonits Márta, Grossman Ashley B, Dutta Pinaki
Аннотация
CONTEXT: Somatotrophinomas can occasionally occur in familial settings and may be associated with known germline mutations, such as MEN1, AIP, CDKN1B, PRKAR1A, SDHx, and MAX. Recently, the CHEK2 gene has emerged as a potential pituitary tumour predisposition gene.
OBJECTIVE: To present a rare case of a patient with a pituitary somatotrophinoma and primary hyperparathyroidism (PHPT) associated with a likely pathogenic CHEK2 germline mutation, suggesting a novel MEN1-like phenotype.
METHODS: We conducted a detailed clinical, biochemical, radiological, and genetic evaluation of a 38-year-old woman presenting with features of acromegaly and PHPT. Genetic testing for known MEN1 syndrome-associated genes and broader pituitary tumour predisposition genes was performed.
RESULTS: The patient presented with features of acromegaly of 3 years duration and a collagenoma. Laboratory evaluation revealed an elevated IGF-1. Biochemical and imaging studies also revealed PTH-dependent hypercalcaemia and bilateral inferior parathyroid adenomas. Genetic testing for a panel of genes causing hypercalcaemia - including MEN1 and CDKN1B - was negative; however, a pathogenic nonsense variant in CHEK2 (c.232C>T; p.(Gln78Ter); gnomAD frequency: 0.0006%) was detected with exome sequencing. The patient underwent transsphenoidal resection of the pituitary tumour followed by gamma-knife radiosurgery and received long-acting octreotide every four weeks. Parathyroidectomy was performed 1.5 years later.
CONCLUSION: This is the first reported case of a CHEK2 germline mutation associated with somatotrophinoma, PHPT, and collagenoma, mimicking the clinical MEN1 syndrome. These findings expand the spectrum of possible CHEK2-associated neoplasia and highlight the need to consider CHEK2 as a possible candidate gene in patients with MEN1-like syndromes when common mutations have been excluded.
OBJECTIVE: To present a rare case of a patient with a pituitary somatotrophinoma and primary hyperparathyroidism (PHPT) associated with a likely pathogenic CHEK2 germline mutation, suggesting a novel MEN1-like phenotype.
METHODS: We conducted a detailed clinical, biochemical, radiological, and genetic evaluation of a 38-year-old woman presenting with features of acromegaly and PHPT. Genetic testing for known MEN1 syndrome-associated genes and broader pituitary tumour predisposition genes was performed.
RESULTS: The patient presented with features of acromegaly of 3 years duration and a collagenoma. Laboratory evaluation revealed an elevated IGF-1. Biochemical and imaging studies also revealed PTH-dependent hypercalcaemia and bilateral inferior parathyroid adenomas. Genetic testing for a panel of genes causing hypercalcaemia - including MEN1 and CDKN1B - was negative; however, a pathogenic nonsense variant in CHEK2 (c.232C>T; p.(Gln78Ter); gnomAD frequency: 0.0006%) was detected with exome sequencing. The patient underwent transsphenoidal resection of the pituitary tumour followed by gamma-knife radiosurgery and received long-acting octreotide every four weeks. Parathyroidectomy was performed 1.5 years later.
CONCLUSION: This is the first reported case of a CHEK2 germline mutation associated with somatotrophinoma, PHPT, and collagenoma, mimicking the clinical MEN1 syndrome. These findings expand the spectrum of possible CHEK2-associated neoplasia and highlight the need to consider CHEK2 as a possible candidate gene in patients with MEN1-like syndromes when common mutations have been excluded.